							Sheet 1	ugust 10 1 Of	3, 20 i
Modified For	m PTO-1	1449	Atty. Docket No.	Atty. Docket No. 3432-US-NP Applicant		Serial No. 10/646,308			
LIS	T OF I	REFERENCES CITED BY	Applicant						
(Use several sheets if necessary)				Fili-a Data	Paul B.J. Burton and Theresa A. Deisher				
				Filing Date	August 21, 2003		Group 1646		
			U.S. PATEN	IT DOCUMENT	-				
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE		NAME		SUB- CLASS	FILING DATE IF APPROPRIATE	
	A1								
	A2					\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			
	A3								
	A4		<u> </u>						
	A5		<u> </u>						
	A6								
		F	FOREIGN PATI	ENT DOCUME	ENTS				
		DOCUMENT NUMBER	DATE	cour	INTRY	CLASS	SUB- CLASS	TRANSL/ YES	ATION NO
	B1								
	B2								
	В3								
	B4								
	B5								
	OTH	IER DOCUMENTS (Incli	uding Publish	er, Author, Tif	tle, Date, Pertin	ent Pag	es, Etc	.)	
	C1	Frémeaux-Bacchi et al., "Functional properties of soluble CD21," Immunopharmacology 42:31-37, 1999.							
	C2	Gaudin et al., "Myocarditis Associated with Doxorubicin Cardiotoxicity," Am J Clin Pathol 100:158-163, 1993.							
	C3	Kwon et al., "4-1BB: Still in the Midst of Darkness," Mol Cells 10(2):119-126, 2000.							
	C4	Pullerits, "Cytokine Modulation for Anti-Allergic Treatment," Current Pharmaceutical Design 8:1845-1853, 2002.							
	C5	Saltiel et al., "Doxorubicin (Adriamycin) Cardiomyopathy," West J Med 3:332-341, 1983.							
	C6	Supplementary European Search Report dated May 20, 2010.							
EXAMINER:		/Dong Jiang/			Date Considered:	11/08/20	 010		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.J./

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.